PT  - JOURNAL ARTICLE
AU  - D E Newby
AU  - F N Witherow
AU  - R A Wright
AU  - P Bloomfield
AU  - C A Ludlam
AU  - N A Boon
AU  - K A A Fox
AU  - D J Webb
TI  - Hypercholesterolaemia and lipid lowering treatment do not affect the acute endogenous fibrinolytic capacity in vivo
AID  - 10.1136/heart.87.1.48
DP  - 2002 Jan 01
TA  - Heart
PG  - 48--53
VI  - 87
IP  - 1
4099  - http://heart.bmj.com/content/87/1/48.short
4100  - http://heart.bmj.com/content/87/1/48.full
SO  - Heart2002 Jan 01; 87
AB  - Objective: To assess acute tissue plasminogen activator (t-PA) release in vivo in patients with hypercholesterolaemia in the presence and absence of lipid lowering treatment and in matched normocholesterolaemic controls. Design: Parallel group comparison and double blind randomised crossover. Setting: University hospital. Patients: Eight patients with hypercholesterolaemia (> 7.8 mmol/l) and eight matched normocholesterolaemic controls (< 5.5 mmol/l). Methods: Blood flow and plasma fibrinolytic factors were measured in both forearms during unilateral brachial artery infusions of the endothelium dependent vasodilator substance P (2–8 pmol/min) and the endothelium independent vasodilator sodium nitroprusside (1–4 μg/min). Interventions: In patients, measurements were made on three occasions: at baseline and after six weeks of placebo or pravastatin 40 mg daily administered in a double blind randomised crossover design. Main outcome measures: Acute release of t-PA. Results: Compared with patients, in normocholesterolaemic control subjects substance P caused greater dose dependent increases in forearm blood flow (p < 0.05) but similar increases in plasma t-PA antigen and activity concentrations. During pravastatin treatment in patients, total serum cholesterol fell by 22% from a mean (SEM) of 8.1 (0.3) to 6.4 (0.4) mmol/l (p = 0.002) and substance P induced vasodilatation was no longer significantly impaired in comparison with controls. However, despite reproducible responses, pravastatin treatment was not associated with significant changes in basal or substance P induced t-PA release. Conclusions: Hypercholesterolaemia and lipid lowering treatment cause no demonstrable effects on acute substance P induced t-PA release in vivo. This suggests that the preventative benefits of lipid lowering treatment are unlikely to be mediated by improvements in endogenous fibrinolysis.